No Detail Found!

Intralesional Epidermal Growth Factor for Diabetic Foot Ulcers

Author(s)
Ekin Ilkeli Department of Cardiovascular Surgery, Duzce State Hospital,Duzce,Turkey
Fethiye Berna Goktas Demircan Department of Plastic and Reconstructive Surgery, Duzce State Hospital,Duzce,Turkey
Ali Cemal Duzgun Department of Cardiovascular Surgery, Ankara Training and Research Hospital,Ankara,Turkey
Hakan Arabaci Department of Infectious Diseases and Clinical Microbiology, Duzce State Hospital,Duzce,Turkey
Ayhan Uysal Department of Cardiovascular Surgery, Faculty of Medicine, Firat University,Elazig,Turkey
Muhip Kanko Department of Cardiovascular Surgery, Faculty of Medicine, Kocaeli University,Turkey
Abstract
Objective: To determine the role of the intralesional recombinant epidermal growth factor (rEGF) in the healing and prevention of extremity amputation in advanced diabetic foot ulcer patients. Study Design: Observational study. Place and Duration of Study: Department of Cardiovascular Surgery, Duzce State Hospital, Duzce, Turkey, between November 2018 and September 2019. Methodology: A total of 58 patients with diabetic foot ulcers that were treated at the study place wereenrolled. The lesions were graded with Wagner Classi cation Syste m.EGF (75 microg of Heberprot-P) vials were stored at +°C4 and cold-chain requirements were followed. EGF 5 mL was dissolved with 0.09% saline solution; and 0.5-1 ml of the solution was injected into the tissues and edge of the lesions regularly. The data was evaluated at the end of two years of the treatment period. The primary objective was wound healing, formation of granulation tissue; and the secondary objective was the prevention of lower extremity amputation. Results: Diabetic foot ulcers wound healing was achieved in 93.1% (n=54) of patients with the formation of granulation tissue. The complete recovery was observed in 94.1% (n=32) of the patients who had Grade III and IV lesions. Lower extremity amputation was performed in two (3.4%) subjects. The lesions of two patients required ap surgery. The most common adverse events were tremor and syncope. Conclusion: Recombinant epidermal growth factor is highly e ective for the treatment of diabetic foot ulcers and prevention of extremity amputation. Intralesional rEGf provides e cient and safe wound healing/closure in patients with diabetic foot ulcers.
Publication Details
Page(s) 278-282
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Diabetic foot, Wound healing, amputation, Epidermal growth factor
0

Citations

0

Downloads

74

Views